Skip to main content
Michael Monostra on Muck Rack

Michael Monostra

Verified
Moorestown Township
As seen in: Healio Endocrinology, Flipboard, EIN News, Endocrine Today, Healio Cardiology, Healio Gastroenterology, Healio Ophthalmology, Healio Primary Care, Healio Women’s Health & OB/GYN, HemOnc Today, Nephrology News & Issues and
Senior Associate Editor for The Sun Newspapers in South Jersey, covering all things Cherry Hill and South Jersey sports.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Michael

Contact Michael, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

GLP-1s may raise risk for smell, taste disturbances in type 2 diabetes Original

|
By Michael Monostra Verified
| Endocrine Today Verified
GLP-1s may raise risk for smell, taste disturbances in type 2 diabetes Add topic to email alerts Receive an email when new articles are posted on Please provide your email address to receive an email when new articles are posted on . Subscribe We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
Open in Who Shared View Duplicates (2) Issue with article?

‘Secret shopper’ study: Most websites prescribe GLP-1s without clinician visit Original

|
By Michael Monostra Verified
| Endocrine Today Verified
A GLP-1 prescription is not a treatment plan. The medication is one tool. The treatment is the comprehensive care surrounding it. The findings from this study are concerning, but unfortunately not surprising. GLP-1 medications have transformed the treatment of obesity and are rapidly becoming foundational therapies across the cardio-kidney-metabolic spectrum. Yet, too often, they are treated like a commodity rather than the powerful prescription therapies they are.
Open in Who Shared View Duplicates (3) Issue with article?

Oral therapy raises annualized height velocity for children with achondroplasia Original

|
By Michael Monostra Verified
| Endocrine Today Verified
Key takeaways: Once-daily infigratinib was tied to a higher increase in annualized height velocity than placebo at 1 year. Of children receiving infigratinib, 8% experienced an adverse event related to treatment. A once-daily oral medication raised annualized height velocity for children and adolescents with achondroplasia, according to data from a phase 3 trial published in The New England Journal of Medicine.
Open in Who Shared View Duplicates (2) Issue with article?
See all 2,121 articles